---
title: "Daiichi Sankyo Company: Q1 FY 2026 revenue up 21% YoY, forecast raised on strong oncology sales and yen weakness"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294542919.md"
description: "Revenue surged 21% YoY in Q1 FY 2026, driven by ENHERTU and DATROWAY, but operating profit fell due to restructuring costs. FY 2026 revenue and profit forecasts were raised, with strong U.S. sales and yen depreciation as key drivers.Based on DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-07-31T17:35:18.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294542919.md)
  - [en](https://longbridge.com/en/news/294542919.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294542919.md)
generator: "portal-rs"
---

# Daiichi Sankyo Company: Q1 FY 2026 revenue up 21% YoY, forecast raised on strong oncology sales and yen weakness

Revenue surged 21% YoY in Q1 FY 2026, driven by ENHERTU and DATROWAY, but operating profit fell due to restructuring costs. FY 2026 revenue and profit forecasts were raised, with strong U.S. sales and yen depreciation as key drivers.

Based on 

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [DSNKY.US](https://longbridge.com/en/quote/DSNKY.US.md)
- [4568.JP](https://longbridge.com/en/quote/4568.JP.md)

## Related News & Research

- [Short Interest in Daiichi Sankyo Co., Ltd. - Sponsored ADR (OTCMKTS:DSNKY) Declines By 38.3%](https://longbridge.com/en/news/297486140.md)
- [Daiichi Sankyo Company (TSE:4568) Dropped, So What Is Behind The Move?](https://longbridge.com/en/news/298059954.md)
- [Daiichi Sankyo’s Enhertu plus pertuzumab wins EU approval for first-line HER2+ metastatic breast cancer](https://longbridge.com/en/news/297606247.md)
- [ANALYSIS-Yen's changing fortunes might finally be spooking the bears](https://longbridge.com/en/news/298005138.md)
- [AstraZeneca, Daiichi Sankyo Get New EU Approval for Breast Cancer Drug](https://longbridge.com/en/news/297613676.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**